Related Experiment Video
Updated: Sep 30, 2026
An Orthotopic Bladder Tumor Model and the Evaluation of Intravesical saRNA Treatment
Published on: July 28, 2012
The role of antisense oligonucleotides in the treatment of bladder cancer
Brian J Duggan1, Sam Gray, Samuel R Johnston
1Department of Urology and Quantitative Pathology, Belfast City Hospital, Belfast, BT12 6BL, Northern Ireland. bjduggan71@hotmail.com
Abstract:
Both intravesical and systemic chemotherapy are limited in their efficacy in the treatment of bladder cancer patients. These limitations are centred around an inability to induce apoptosis in bladder tumour cells. This resistance to apoptosis induction is commonly associated with the overexpression of antiapoptotic proteins such as Bcl-2. Strategies to decrease the cellular expression of such proteins would enhance chemotherapy effectiveness. One such strategy is to use antisense oligonucleotides which are short sequence specific single stranded DNA or RNA molecules designed to bind to the RNA of the target protein. By binding to the target RNA, protein production is interrupted and target protein levels decease. When used to target antiapoptotic proteins, antisense oligonucleotides can therefore be used as a pre-treatment before chemotherapy to help chemosensitise the tumour cell. This review outlines the rationale for this strategy and the work done to date with antisense oligonucleotides in bladder cancer.
Insights
Antisense oligonucleotides can overcome chemotherapy resistance in bladder cancer by reducing antiapoptotic proteins. This strategy enhances tumor cell apoptosis, improving treatment efficacy.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Chemotherapy for bladder cancer has limited efficacy due to tumor cell resistance to apoptosis.
- Overexpression of antiapoptotic proteins, like Bcl-2, contributes to this resistance.
- Targeting these proteins is crucial for enhancing chemotherapy effectiveness.
Purpose of the Study:
- To review the rationale and current research on using antisense oligonucleotides (ASOs) in bladder cancer treatment.
- To explore ASOs as a strategy to chemosensitize bladder tumor cells.
Main Methods:
- Antisense oligonucleotides are single-stranded DNA or RNA molecules designed to bind to specific target RNA.
- This binding interrupts protein production, leading to decreased target protein levels.
- ASOs targeting antiapoptotic proteins can be used as a pre-treatment to enhance chemotherapy.
Main Results:
- ASOs offer a strategy to decrease cellular expression of antiapoptotic proteins.
- This reduction in antiapoptotic proteins can chemosensitize bladder tumor cells.
- The review consolidates existing work on ASOs in bladder cancer.
Conclusions:
- Antisense oligonucleotides hold promise for overcoming chemotherapy resistance in bladder cancer.
- Targeting antiapoptotic proteins with ASOs represents a viable approach to improve treatment outcomes.
- Further research and application of ASOs could significantly benefit bladder cancer patients.
Related Concept Videos
02:30siRNA - Small Interfering RNAs
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:15Experimental RNAi
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...